Which cardiovascular risk tables should we use?;¿Qué tablas de riesgo cardiovascular debemos utilizar?

Revista Espanola de Cardiologia

Volumn 60, Issue 7, 2007, Pages 690-692

  Masana, Lluís ^a,b  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; EDITORIAL; HUMAN; HYPERTENSION; LIFESTYLE; OBESITY; PREVENTION AND CONTROL; RISK FACTOR; LIFE TABLE; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; HUMANS; LIFE TABLES; RISK ASSESSMENT;

EID: 34548028199     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13108273     Document Type: Editorial

References (12)

1. Masana L. Determinación del riesgo cardiovascular global. ¿Una utopía? Med Clin (Barc). 2004;123:702-3.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
3. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9.
4. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-9.
5. Comín E, Solanas P, Cabezas C, Subirana I, Ramos R, et al. Rendimiento de la estimación del riesgo cardiovascular en España utilizando distintas funciones. Rev Esp Cardiol. 2007;60:693-702.
6. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health. 2003;57:634-8.
7. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conthe P, et al. Adaptación española de las guías europeas de prevencion cardiovascular. Rev Esp Salud Publica. 2004;78:435-8.
8. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
9. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
10. Lahoz C, Mostaza JM. Índice tobillo-brazo: una herramienta útil para estratificar el riesgo cardiovascular. Rev Esp Cardiol. 2006;59:647-9.
11. Campuzano R, Moya JL, García-Lledo A, Salido L, Guzman G, Tomas JP, et al. Disfunción endotelial y grosor íntima-media en relación a los factores de riesgo cardiovascular en pacientes sin manifestaciones clínicas de arteriosclerosis. Rev Esp Cardiol. 2003;56:546-54.
12. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient - Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98:2H-15H.